MarketPeel
Insider Trading Intelligence
SM

Stephen F. Mahoney

VRDN
PRESIDENT AND CEO · VIRIDIAN THERAPEUTICS, INC.DE · CIK 0001741389
FILING MIX · LIFETIME70%/30%
BUYS
7
SELLS
3
TOTAL VALUE
$946.5K
COMPANIES
1
ACTIVE SINCE
Oct 2023
HOLDINGS NOW
33,349
AVG SELL PX
$29.75
TRADE KIND
SHOWING 10 / 10
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 1 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Stephen F. Mahoney, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+100.00%+2.53%+0.26%+2.27%+2.27%
14d1+100.00%+1.29%+1.42%-0.13%-0.13%
30d1+0.00%-0.21%+1.64%-1.85%-1.85%
60d1+0.00%-6.09%+5.11%-11.19%-11.19%
90d1+0.00%-15.00%+5.58%-20.58%-20.58%
180d1+0.00%-39.31%+0.13%-39.44%-39.44%
1y1+0.00%-13.46%+16.55%-30.01%-30.01%
2y1(1 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
VRDN · 33,349 shares · as of Mar 3, 2026
0314,850629,700944,5501,259,400202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 7 buys / 3 sellsCOVERAGE · 10 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
PURCHASE
President and CEO
18,35740,757Mar 3, 2026Mar 4, 2026View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
SALE
President and CEO
18,35755,071Mar 3, 2026Mar 4, 2026View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
SALE
President and CEO
7,627$29.32$223.6K33,130Mar 3, 2026Mar 4, 2026View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
SALE
President and CEO
7,408$30.19$223.6K33,349Mar 3, 2026Mar 9, 2026View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
PURCHASEGRANT
Stock grant
111,900111,900Mar 2, 2026Mar 4, 2026View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
PURCHASEGRANT
Stock grant
559,600559,600Mar 2, 2026Mar 4, 2026View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
PURCHASEGRANT
Stock grant
73,42873,428Mar 3, 2025Mar 4, 2025View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
PURCHASEGRANT
Stock grant
440,565440,565Mar 3, 2025Mar 4, 2025View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
PURCHASE
President and CEO
21,400$23.33$499.3K21,400Sep 27, 2024Sep 30, 2024View →
VRDN
VIRIDIAN THERAPEUTICS, INC.DE
PURCHASEGRANT
Stock grant
1,259,4001,259,400Oct 30, 2023Nov 1, 2023View →
Other insiders · VRDN
Loading peer insiders…
About this filer
CIK 0001741389
ROLE
President and CEO
PRIMARY
VRDN
COMPANIES
1
ACTIVE SINCE
Oct 2023
MARKETPEEL · /INSIDER/0001741389DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback